Home > Neurology > AAN 2019 > Headache and Migraine > Fremanezumab efficacy and safety maintained over 1 year

Fremanezumab efficacy and safety maintained over 1 year

Conference
AAN 2019
Results of a 1-year multicentre, randomised, double-blind, parallel-group study showed sustained effectiveness of the calcitonin gene-related peptide receptor antagonist fremanezumab in chronic and episodic migraine patients [1]. Included in this analysis were 1,494 patients who had received subcutaneous fremanezumab either monthly (225 mg; chronic migraine starting dose of 675 mg), or quarterly (675 mg) at least 12 months. In chronic migraine patients (n=1,110), the mean change in monthly migraine days was -8.1 and -7.2 days in the monthly and quarterly groups, respectively. The ≥50% response rate was 57% and 53%. The number of headache days of at least moderate severity decreased similarly: -6.8 and -6.4 days. In episodic migraine patients (n=780), the mean change in monthly migraine days was -5.1 and -5.2 days in the monthly and quarterly groups, with a ≥50% response rate of 68% and 66%. Headache days of at least moderate severity decreased by -4.2 and ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on